title: Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP.
abstract: In patients with intermediate or high grade non-Hodgkin lymphoma (NHL), third generation chemotherapy regimens have been introduced to improve survival in comparison with the standard CHOP regimen. However, most studies have found no difference between these two treatments. We conducted a meta-analysis to assess the effectiveness of third generation regimens as compared with CHOP. Our study included the randomized controlled trials published in English from 1970 to 1999. After a Medline search, 5 trials were found to meet our inclusion criteria. A total of 1982 patients, that were enrolled in these trials, were included in the survival meta-analysis. Our methodology retrieved patient-level information from all of these subjects; survival up to 9 years after randomization was compared between the two treatment options. The results of our meta-analysis showed that, in comparison with CHOP, third generation chemotherapy did not prolong survival at levels of statistical significance (chi-square by log-rank test = 1.44, P = 0.23). The relative death risk for third generation regimens vs. CHOP was 0.92 (95%CI: 0.80 to 1.06;P = 0.26). We conclude that, on the basis of our meta-analysis, third generation regimens do not confer any survival benefit to patients with intermediate or high grade NHL as compared with CHOP.
authors.affiliation: Drug Information Center Azienda Ospedaliera Careggi, Firenze, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Messori
authors.forename: M
authors.initials: M
authors.lastname: Vaiani
authors.forename: S
authors.initials: S
authors.lastname: Trippoli
authors.forename: L
authors.initials: L
authors.lastname: Rigacci
authors.forename: M
authors.initials: M
authors.lastname: Jerkeman
authors.forename: G
authors.initials: G
authors.lastname: Longo
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D001761:Bleomycin; D003520:Cyclophosphamide; D003561:Cytarabine; D004317:Doxorubicin; D005472:Fluorouracil; D006801:Humans; D002955:Leucovorin; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008727:Methotrexate; D011241:Prednisone; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D014750:Vincristine
chemical_list: D003561:Cytarabine; D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002955:Leucovorin; D005472:Fluorouracil; D011241:Prednisone; D008727:Methotrexate